AMTI - Applied Molecular stock falls amid results of phase 2 trial of AMT-101 in pouchitis

Applied Molecular Transport (NASDAQ:AMTI) reported data from a phase 2 trial of AMT-101 to treat patients with chronic pouchitis. Pouchitis is an inflammation that occurs in the lining of a pouch which is created during surgery to treat ulcerative colitis (UC). In certain patients with UC, part of the diseased colon is removed and the bowel reconnected in a procedure called Ileal pouch-anal anastomosis. In the surgery, the end of the small intestine is used to create a pouch which is attached internally to the area above the anus to hold waste before elimination. Pouchitis is characterized by symptoms of excessive stool frequency, urgency and fecal incontinence, among others. The efficacy goals of phase 2 trial, dubbed FILLMORE, were to measure symptomatic improvement, as measured by stool frequency response; and histologic healing. The trial evaluated 3-mg and 10-mg doses of the drug. The company said data showed that 36.4% (8/22) of patients achieved stool frequency

For further details see:

Applied Molecular stock falls amid results of phase 2 trial of AMT-101 in pouchitis